Clinico-biological Collection of Subjects With Hyper Lipoprotein a in Reunion Island

Not Applicable

• Conditions: Cardiovascular Disease
• Interventions: Other: blood lipoprotein (a) test

• Registration Number: NCT04310917
• Lead Sponsor: Centre Hospitalier Universitaire de la Réunion

Brief Summary

Cardiovascular disease (CVD) is the second leading cause of death in France and the leading cause of death on Reunion Island. Some modifiable risk factors for cardiovascular diseases are well identified and can be easily modulated, in particular by hygiene and dietetic measures (tobacco, sedentary lifestyle). Other risk factors such as high blood pressure, diabetes or dyslipidemia can also be pharmacologically modulated. On the other hand, there is a cardiovascular risk factor that we do not know how to modulate: a high level of lipoprotein (a) (Lp (a)), whose regulation remains largely unknown.

High plasma levels of Lipoprotein (a) remain a major risk for the development of cardiovascular disease and its clinical complications, which no drug can currently reduce. Understanding the biological and genetic determinants modulating Lp (a) levels remains a major challenge for treating subjects with hyper Lp (a). Several individuals and possibly Reunion families have been detected as having abnormally high rates of apo (a)

Thanks to the link between cardiovascular clinical picture, Lp (a) concentration and other biological markers, the study should allow a better understanding of the mechanisms underlying the cardiovascular risk in order to offer advice. prevention and care of at-risk subjects screened; or even avenues for adapted genetic counseling (DNA sequencing).

At the genetic level, several hypotheses could be explored making it possible to link the expression of the apo (a) protein to the genotype, in particular the presence of mutations in the gene, in the promoter region, polymorphisms, or epistatic regulation.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2020-03-13
• Study First Submitted QC: 2020-03-13
• Study First Posted: 2020-03-17
• Study Start: 2020-09-19
• Status Verified: 2022-08
• Last Update Submitted: 2022-08-29
• Last Update Posted: 2022-08-30
• Primary Completion: 2023-03
• Study Completion: 2023-06

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

• Patient with Lp (a)> 200 nmol / L OR member of family of a patient with Lp (a)> 200 nmol / L
• be affiliated or beneficiary of a social security scheme
• signed consent

Exclusion Criteria

• Refusal to participate

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Lipoprotein a level	blood lipoprotein (a) test	blood lipoprotein (a) test

Primary Outcome Measures

Name	Time	Method
Carry out a family screening of the plasma Lp (a) level	at inclusion	Carry out a family screening of the plasma Lp (a) level around index cases followed or directed towards Reunion University Hospital (index case = Lp (a) rate\> 200nmol / L)

Trial Locations

Locations (1)

Centre Hospitalier Universitaire de la Réunion; 🇫🇷 Saint-Denis, France